Personalis Announces Scientific Collaboration with Sarepta Therapeutics on Immune Response to Precision Genetic Therapeutics

MENLO PARK, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL) today announced a collaboration with Sarepta Therapeutics (Nasdaq: SRPT), a leader in precision genetic medicine for rare disease. As part of this research collaboration, Sarepta will be working with the Personalis team to characterize immune response to precision genetic therapeutics, utilizing Personalis’ advanced proprietary analytics.

“We are excited to announce this collaboration with Personalis. By bringing together Sarepta’s expertise in precision genetic medicine and Personalis’ advanced neoepitope prediction, our goal is to better characterize certain types of immune response to benefit patients with rare disease,” said Dr. Tanya Teslovich, Senior Director, Genomics at Sarepta.

“We are excited to work with Sarepta to apply our proprietary analytics in the rapidly emerging area of genetic medicine. This collaboration demonstrates the extensibility of our technology platform beyond cancer to additional therapy development areas,” said Dr. Richard Chen, CSO at Personalis.

About Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis ImmunoID NeXT Platform™ is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

Check Also

MEI Pharma and Helsinn Group Discontinue Phase 3 Study of Pracinostat in AML After Interim Analysis

Lugano, Switzerland and San Diego, USA, July 2, 2020 – Helsinn, a Swiss pharmaceutical group focused …